These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 27159593

  • 1. Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation.
    Ko K, Wang J, Perper S, Jiang Y, Yanez D, Kaverina N, Ai J, Liarski VM, Chang A, Peng Y, Lan L, Westmoreland S, Olson L, Giger ML, Chun Wang L, Clark MR.
    Arthritis Rheumatol; 2016 Nov; 68(11):2740-2751. PubMed ID: 27159593
    [Abstract] [Full Text] [Related]

  • 2. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.
    Moser K, Kalies K, Szyska M, Humrich JY, Amann K, Manz RA.
    Arthritis Rheum; 2012 Apr; 64(4):1237-46. PubMed ID: 22006377
    [Abstract] [Full Text] [Related]

  • 3. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis.
    Kinloch AJ, Chang A, Ko K, Henry Dunand CJ, Henderson S, Maienschein-Cline M, Kaverina N, Rovin BH, Salgado Ferrer M, Wolfgeher D, Liarski V, Haddon DJ, Utz PJ, Wilson PC, Clark MR.
    Arthritis Rheumatol; 2014 Dec; 66(12):3359-70. PubMed ID: 25306868
    [Abstract] [Full Text] [Related]

  • 4. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.
    Peperzak V, Slinger E, Ter Burg J, Eldering E.
    Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871
    [Abstract] [Full Text] [Related]

  • 5. Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus.
    Benigni A, Caroli C, Longaretti L, Gagliardini E, Zoja C, Galbusera M, Moioli D, Romagnani P, Tincani A, Andreoli L, Remuzzi G.
    Arthritis Rheum; 2007 May; 56(5):1569-78. PubMed ID: 17469139
    [Abstract] [Full Text] [Related]

  • 6. The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis.
    Clark MR, Trotter K, Chang A.
    Semin Nephrol; 2015 Sep; 35(5):455-64. PubMed ID: 26573548
    [Abstract] [Full Text] [Related]

  • 7. Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-α production.
    Zhan Y, Carrington EM, Ko HJ, Vikstrom IB, Oon S, Zhang JG, Vremec D, Brady JL, Bouillet P, Wu L, Huang DC, Wicks IP, Morand EF, Strasser A, Lew AM.
    Arthritis Rheumatol; 2015 Mar; 67(3):797-808. PubMed ID: 25418983
    [Abstract] [Full Text] [Related]

  • 8. Anti-tumor necrosis factor α treatment of interferon-α-induced murine lupus nephritis reduces the renal macrophage response but does not alter glomerular immune complex formation.
    Bethunaickan R, Sahu R, Liu Z, Tang YT, Huang W, Edegbe O, Tao H, Ramanujam M, Madaio MP, Davidson A.
    Arthritis Rheum; 2012 Oct; 64(10):3399-408. PubMed ID: 22674120
    [Abstract] [Full Text] [Related]

  • 9. Reduced fragmentation of apoptotic chromatin is associated with nephritis in lupus-prone (NZB x NZW)F(1) mice.
    Zykova SN, Seredkina N, Benjaminsen J, Rekvig OP.
    Arthritis Rheum; 2008 Mar; 58(3):813-25. PubMed ID: 18311834
    [Abstract] [Full Text] [Related]

  • 10. The role of aldosterone blockade in murine lupus nephritis.
    Monrad SU, Killen PD, Anderson MR, Bradke A, Kaplan MJ.
    Arthritis Res Ther; 2008 Mar; 10(1):R5. PubMed ID: 18197980
    [Abstract] [Full Text] [Related]

  • 11. Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice.
    Lui SL, Yung S, Tsang R, Zhang F, Chan KW, Tam S, Chan TM.
    Lupus; 2008 Apr; 17(4):305-13. PubMed ID: 18413412
    [Abstract] [Full Text] [Related]

  • 12. FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis.
    Bergtold A, Gavhane A, D'Agati V, Madaio M, Clynes R.
    J Immunol; 2006 Nov 15; 177(10):7287-95. PubMed ID: 17082647
    [Abstract] [Full Text] [Related]

  • 13. Curcumin attenuates lupus nephritis upon interaction with regulatory T cells in New Zealand Black/White mice.
    Lee H, Kim H, Lee G, Chung HS, Bae H.
    Br J Nutr; 2013 Jul 14; 110(1):69-76. PubMed ID: 23181951
    [Abstract] [Full Text] [Related]

  • 14. The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice.
    Sitrin J, Suto E, Wuster A, Eastham-Anderson J, Kim JM, Austin CD, Lee WP, Behrens TW.
    J Immunol; 2017 Aug 15; 199(4):1238-1249. PubMed ID: 28696253
    [Abstract] [Full Text] [Related]

  • 15. Brief Report: Tubulointerstitial Damage in Lupus Nephritis: A Comparison of the Factors Associated With Tubulointerstitial Inflammation and Renal Scarring.
    Londoño Jimenez A, Mowrey WB, Putterman C, Buyon J, Goilav B, Broder A.
    Arthritis Rheumatol; 2018 Nov 15; 70(11):1801-1806. PubMed ID: 29851285
    [Abstract] [Full Text] [Related]

  • 16. Critical comparative analyses of anti-alpha-actinin and glomerulus-bound antibodies in human and murine lupus nephritis.
    Kalaaji M, Sturfelt G, Mjelle JE, Nossent H, Rekvig OP.
    Arthritis Rheum; 2006 Mar 15; 54(3):914-26. PubMed ID: 16508974
    [Abstract] [Full Text] [Related]

  • 17. The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture.
    Hainz N, Thomas S, Neubert K, Meister S, Benz K, Rauh M, Daniel C, Wiesener M, Voll RE, Amann K.
    Nephron Exp Nephrol; 2012 Mar 15; 120(2):e47-58. PubMed ID: 22286140
    [Abstract] [Full Text] [Related]

  • 18. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S, Trick D, Sondermann P, Kamino K, Schlegelberger B, Kniesch K, Tiede A, Jacob U, Schmidt RE, Witte T.
    Ann Rheum Dis; 2008 Feb 15; 67(2):154-61. PubMed ID: 17557887
    [Abstract] [Full Text] [Related]

  • 19. Immunolocalization of fibroblast growth factor-1 (FGF-1), its receptor (FGFR-1), and fibroblast-specific protein-1 (FSP-1) in inflammatory renal disease.
    Rossini M, Cheunsuchon B, Donnert E, Ma LJ, Thomas JW, Neilson EG, Fogo AB.
    Kidney Int; 2005 Dec 15; 68(6):2621-8. PubMed ID: 16316338
    [Abstract] [Full Text] [Related]

  • 20. Semaphorin3A: A Potential Therapeutic Tool for Lupus Nephritis.
    Bejar J, Kessler O, Sabag AD, Sabo E, Itzhak OB, Neufeld G, Vadasz Z.
    Front Immunol; 2018 Dec 15; 9():634. PubMed ID: 29670620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.